BWAY
Brainsway Ltd.
$14.41
+3.74%
$577.7M
No data for this timeframe.
Vol
Market Cap$577.7M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders4 funds
Inst. Value$8.0M
Inst. Activity0 buys / 2 sells
Insider Activity0B / 4S
SEC Reports2
Press Releases4
Exchange OTC·Sector Surgical & Medical Instruments & Apparatus·Inc. L3·CIK 0001505065·Prev Close $13.89
Recent Activity
Jun 9, 2026
routine
BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting
Preliminary Data Analysis Reveals Over 80% Remission Rate One Year after Accelerated Deep TMS Treatm
Jun 2, 2026
Insider
Roth Yiftach sold 1,000 shares
Chief Scientist @ $0.00 ($0.00)
Jun 1, 2026
Insider
Roth Yiftach sold 2,000 shares
Chief Scientist @ $0.00 ($0.00)
May 26, 2026
Insider
Mitrany Rayten Michal Ety sold 7,980 shares
Director @ $0.00 ($0.00)
May 18, 2026
Press
BrainsWay announced a strategic minority investment of $1.5M (with potential $1.5M in milestone-based investments) in Ho
Impact 4/10
May 13, 2026
SEC
BrainsWay reported Q1 2026 revenue of $15.5M (+35% YoY) and net income of $2.3M (+107% YoY), both well above consensus e
PRESS-RELEASE — Impact 8/10
Mar 26, 2026
SEC
BrainsWay completed a $6 million milestone-based convertible loan to Neurolief following FDA approval of Neurolief's Pro
6-K — Impact 7/10
Inst.
TWO SIGMA INVESTMENTS, LP — TRIM
75,691 shares ($1.4M)
Price Targets
$16.67
+15.5% upside
Buy
Current $14.43
Low $15.00
Median $17.00
High $18.00
3 analysts
$15.00
$18.00
Analyst Ratings
3Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 12, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jan 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.07 ▲ +10.5% | $0.05 — $0.10 | 180% YoY | 3 |
| Next Q | $0.09 | $0.06 — $0.13 | 333% YoY | 3 |
| Current FY | $0.30 ▼ -1.1% | $0.24 — $0.42 | 69% YoY | 3 |
| Next FY | $0.47 ▲ +4.5% | $0.32 — $0.69 | 54% YoY | 3 |
Latest Reports
NEUTRAL
Press
4/10
BrainsWay announced a strategic minority investment of $1.5M (with potential $1.5M in milestone-based investments) in Ho
May 18, 2026
BULLISH
PRESS-RELEASE
8/10
BrainsWay reported Q1 2026 revenue of $15.5M (+35% YoY) and net income of $2.3M (+107% YoY), both well above consensus e
May 13, 2026
BULLISH
6-K
7/10
BrainsWay completed a $6 million milestone-based convertible loan to Neurolief following FDA approval of Neurolief's Pro
Mar 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | $5.3M | — |
| TWO SIGMA INVESTMENTS, LP | $1.4M | TRIM |
| MORGAN STANLEY | $877.9K | ADD |
| WELLS FARGO & COMPANY/MN | $383.3K | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 2, 2026 | Roth Yiftach | SELL | $0.00 |
| Jun 1, 2026 | Roth Yiftach | SELL | $0.00 |
| May 26, 2026 | Mitrany Rayten | SELL | $0.00 |
| May 25, 2026 | Mitrany Rayten | SELL | $0.00 |
| May 20, 2026 | Mitrany Rayten | M | $0.00 |
4 institutional holders with $8.0M total value (418,862 shares) as of 2025-Q4. Top holders: RENAISSANCE, TWO, MORGAN. Net selling activity: 2 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES LLC | 276,860 | $5.3M | 66.1% | — |
| 2 | TWO SIGMA INVESTMENTS, LP | 75,691 | $1.4M | 18.1% | TRIM -26.4% |
| 3 | MORGAN STANLEY | 46,158 | $877.9K | 11.0% | ADD +43.2% |
| 4 | WELLS FARGO & COMPANY/MN | 20,153 | $383.3K | 4.8% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | TRIM | 102,902 | 75,691 | -26.4% | $1.4M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | EXIT | 7,102 | 0 | -100.0% | $0.00 | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 82,196 | 102,902 | +25.2% | $1.6M | 2025-Q3 |
| UBS Group AG | DOUBLED | 3,001 | 63,878 | +2028.6% | $962.6K | 2025-Q3 |
| MORGAN STANLEY | ADD | 30,375 | 43,492 | +43.2% | $655.4K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | NEW | — | 20,118 | — | $303.2K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEW | — | 7,102 | — | $107.0K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 28,072 | 3,001 | -89.3% | $39.5K | 2025-Q2 |
| CITADEL ADVISORS LLC | DOUBLED | 32,133 | 145,910 | +354.1% | $1.4M | 2025-Q1 |
| MORGAN STANLEY | ADD | 19,343 | 30,258 | +56.4% | $286.5K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 70 | 5 | -92.9% | $47.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 53,160 | 32,133 | -39.6% | $303.0K | 2024-Q4 |
| UBS Group AG | DOUBLED | 1,659 | 27,471 | +1555.9% | $259.1K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 80 | 19,343 | +24078.8% | $182.4K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 2,717 | 70 | -97.4% | $660.00 | 2024-Q4 |
2 unique insiders with 4 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | Roth Yiftach | Chief Scientist | SELL | 1,000 | $0.00 | $0.00 |
| Jun 1, 2026 | Roth Yiftach | Chief Scientist | SELL | 2,000 | $0.00 | $0.00 |
| May 26, 2026 | Mitrany Rayten Michal Ety | Director | SELL | 7,980 | $0.00 | $0.00 |
| May 25, 2026 | Mitrany Rayten Michal Ety | Director | SELL | 10,000 | $0.00 | $0.00 |
| May 20, 2026 | Mitrany Rayten Michal Ety | Director | M | 17,500 | $0.00 | $0.00 |
| May 20, 2026 | Mitrany Rayten Michal Ety | Director | F | 6,080 | $0.00 | $0.00 |
| May 20, 2026 | Mitrany Rayten Michal Ety | Director | M | 17,500 | $0.00 | $0.00 |
| May 19, 2026 | Mitrany Rayten Michal Ety | Director | M | 10,000 | $0.00 | $0.00 |
| May 19, 2026 | Mitrany Rayten Michal Ety | Director | F | 3,440 | $0.00 | $0.00 |
| May 19, 2026 | Mitrany Rayten Michal Ety | Director | M | 10,000 | $0.00 | $0.00 |
2 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 0 neutral. Avg impact: 7.5/10.
NEUTRAL
4/10
BrainsWay announced a strategic minority investment of $1.5M (with potential $1.5M in milestone-base
May 18, 2026
BULLISH
7/10
BrainsWay completed a $6 million milestone-based convertible loan to Neurolief following FDA approva
Mar 26, 2026
BULLISH
8/10
BrainsWay reported strong Q4 and full-year 2025 results with 27% YoY revenue growth to $52.2 million
Mar 11, 2026
BULLISH
8/10
BrainsWay released new clinical data demonstrating that its FDA-cleared SWIFT™ accelerated Deep TMS
Mar 4, 2026
Current analyst consensus: Strong Buy (86% buy). Based on 7 analysts: 3 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$16.67 mean target
+15.5% upside
Buy (3.00)
$15.00 Low
$18.00 High
| Metric | Value |
|---|---|
| Current Price | $14.43 |
| Target Low | $15.00 |
| Target Mean | $16.67 |
| Target Median | $17.00 |
| Target High | $18.00 |
| # Analysts | 3 |
| Recommendation | Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.07 | $0.05 | $0.10 | 180.0% | +10.5% | 1↑ 0↓ | $0.0B | 29.1% | 3 |
| Next Q 2026-09-30 |
$0.09 | $0.06 | $0.13 | 333.4% | +0.0% | 1↑ 1↓ | $0.0B | 28.4% | 3 |
| Current FY 2026-12-31 |
$0.30 | $0.24 | $0.42 | 68.5% | -1.1% | 3↑ 0↓ | $0.1B | 28.6% | 3 |
| Next FY 2027-12-31 |
$0.47 | $0.32 | $0.69 | 53.8% | +4.5% | 1↑ 0↓ | $0.1B | 23.1% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.070 | |
| 7d ago | $0.050 | +0.020 |
| 30d ago | $0.063 | +0.007 |
| 60d ago | $0.063 | +0.007 |
| 90d ago | $0.028 | +0.042 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 12, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
routine
BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting
Preliminary Data Analysis Reveals Over 80% Remission Rate One Year after Accelerated Deep TMS Treatment, with Decline in Severe Functional Impairment
May 18, 2026
contract
BrainsWay Announces Minority-Stake Investment in Hopemark Health
Investment in provider servicing clinics in Illinois is latest in series of similar transactions by BrainsWay with leading North American mental healt
May 13, 2026
earnings
BrainsWay Reports First Quarter 2026 Financial Results and Operational Highlights
<p align="center"><em>R</em><em>evenue grew approximately</em><em> </em><em>35</em><em>% </em><em>y</em><em>ear-</em><em>o</em><em>ver-</em><em>y</em>
Apr 29, 2026
announcement
BrainsWay to Report First Quarter 2026 Financial Results on May 13, 2026
<p>BURLINGTON, Mass. and JERUSALEM, April 29, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a gl
Apr 15, 2026
other
BrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) Therapy
Growing payer acceptance of nurse practitioner administration of Deep TMS is expected to expand access to non‑drug mental health treatments <pre>Growi
Apr 13, 2026
other
BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference
<p align="left">BURLINGTON, Mass. and JERUSALEM, April 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Co
Mar 26, 2026
activist
BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD
<p align="justify">BURLINGTON, Mass. and JERUSALEM, March 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the
Mar 19, 2026
other
BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health
BrainsWay’s investment is part of its ongoing strategy to partner with leading U.S. mental health providers to increase access to care <pre>BrainsWay’
Mar 11, 2026
earnings
BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
<p align="center"><em>Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million</em></p>
Mar 4, 2026
fda
Landmark Data Validate BrainsWay’s SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment
World’s only FDA-cleared Deep TMS™ accelerated treatment reduces the acute phase of treatment by 70% <pre>World’s only FDA-cleared Deep TMS™ accelerat